Patents by Inventor German Bou Arevalo
German Bou Arevalo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220243248Abstract: A method of rapidly evaluating the susceptibility of a strain of bacteria to a cell wall synthesis inhibiting antibiotic based on an assessment of cell enlargement in response to doses of the cell wall synthesis inhibiting antibiotic which are correlated to breakpoints of bacterial susceptibility.Type: ApplicationFiled: April 25, 2022Publication date: August 4, 2022Applicant: ABM TECHNOLOGIES, LLCInventors: José Luis FERNÁNDEZ GARCÍA, Jaime GOSÁLVEZ BERENGUER, Rebeca SANTISO BRANDARIZ, Maria TAMAYO NOVAS, Germán BOU ARÉVALO
-
Patent number: 11319574Abstract: A method of rapidly evaluating the susceptibility of a strain of bacteria to a cell wall synthesis inhibiting antibiotic based on an assessment of cell enlargement in response to doses of the cell wall synthesis inhibiting antibiotic which are correlated to breakpoints of bacterial susceptibility.Type: GrantFiled: July 2, 2014Date of Patent: May 3, 2022Assignee: ABM Technologies, LLCInventors: Jose Luis Fernandez Garcia, Jaime Gosalvez Berenguer, Rebeca Santiso Brandariz, Maria Tamayo Novas, German Bou Arevalo
-
Patent number: 11197922Abstract: The present invention refers to a method for the production of live attenuated bacterial strains, suitable as vaccine candidates, comprising the steps of: A. providing a bacterial strain capable of expressing glutamate racemase and possibly D-amino acid transaminase and comprising a peptidoglycan cell wall, and B. inactivating the gene or genes encoding for the glutamate racemase enzyme and, if needed, the gene or genes encoding for the enzyme D-amino acid transaminase in such way that the bacterial strain is no longer capable of expressing a functional glutamate racemase and/or a functional D-amino acid transaminase; wherein the inactivation of said genes causes said bacterial strain to be auxotrophic for D-glutamate.Type: GrantFiled: November 14, 2019Date of Patent: December 14, 2021Assignees: SERVICIO GALEGO DE SAÚDE (SERGAS), FUNDACIÓN PROFESOR NOVOA SANTOSInventors: Germán Bou Arévalo, María Clara Póvoa Cabral, Astrid Pérez Gómez, María Merino Carballeira, Alejandro Beceiro Casas, Patricia García Fernández
-
Publication number: 20200206337Abstract: The present invention refers to a method for the production of live attenuated bacterial strains, suitable as vaccine candidates, comprising the steps of: A. providing a bacterial strain capable of expressing glutamate racemase and possibly D-amino acid transaminase and comprising a peptidoglycan cell wall, and B. inactivating the gene or genes encoding for the glutamate racemase enzyme and, if needed, the gene or genes encoding for the enzyme D-amino acid transaminase in such way that the bacterial strain is no longer capable of expressing a functional glutamate racemase and/or a functional D-amino acid transaminase; wherein the inactivation of said genes causes said bacterial strain to be auxotrophic for D-glutamate.Type: ApplicationFiled: November 14, 2019Publication date: July 2, 2020Inventors: Germán Bou Arévalo, María Clara Póvoa Cabral, Astrid Pérez Gómez, María Merino Carballeira, Alejandro Beceiro Casas, Patricia García Fernández
-
Patent number: 10517939Abstract: The present invention refers to a method for the production of live attenuated bacterial strains, suitable as vaccine candidates, comprising the steps of: A. providing a bacterial strain capable of expressing glutamate racemase and possibly D-amino acid transaminase and comprising a peptidoglycan cell wail, and B. inactivating the gene or genes encoding for the glutamate racemase enzyme and, if needed, the gene or genes encoding for the enzyme D-amino acid transaminase in such way that the bacterial strain is no longer capable of expressing a functional glutamate racemase and/or a functional D-amino acid transaminase; wherein the inactivation of said genes causes said bacterial strain to be auxotrophic for D-glutamate.Type: GrantFiled: October 13, 2014Date of Patent: December 31, 2019Assignees: SERVICIO GALEGO DE SAÚDE (SERGAS), FUNDACIÓN PROFESOR NOVOA SANTOSInventors: Germán Bou Arévalo, María Clara Póvoa Cabral, Astrid Pérez Gómez, María Merino Carballeira, Alejandro Beceiro Casas, Patricia García Fernández
-
Patent number: 10472663Abstract: The present invention relates to a method for the rapid evaluation of bacterial susceptibility or non-susceptibility of bacteria to antibiotics that inhibit protein synthesis. The rationale is to identify bacterial responses that depend or are influenced by protein synthesis. If this response is prevented or reduced by the antibiotic that inhibits the protein synthesis, the bacteria are susceptible to this antibiotic. Otherwise, if the response keeps similar despite the incubation with the antibiotic, the bacteria are not susceptible or resistant to this antibiotic. These responses could be determined at the DNA lev-el, cell wall level, morphological level or any other experimental approach, including metabolic, bio-chemical, physiological or genetic processes.Type: GrantFiled: January 19, 2016Date of Patent: November 12, 2019Assignee: ABM Technologies, LLCInventors: José Luis Fernández García, Jaime Gosálvez Berenguer, Germán Bou Arévalo, Maria Tamayo Novas, Rebeca Santiso Brandariz, Fátima María Otero Fariña
-
Patent number: 9976170Abstract: The present invention relates to a method for evaluating the integrity of the cell wall of the bacteria present in a culture in the presence of an antibiotic acting on the bacterial cell wall which, from a practical point of view, allows quickly determining if a bacterium is sensitive or resistant to an antibiotic acting on the bacterial cell wall. Likewise, the present invention also relates to a lysis solution applicable in the preceding method, specifically affecting bacteria having the cell wall damaged by the action of an antibiotic acting on the bacterial cell wall, which allows distinguishing bacteria sensitive to said antibiotic from those resistant to said antibiotic.Type: GrantFiled: July 26, 2012Date of Patent: May 22, 2018Assignee: UNIVERSIDAD AUTONOMA DE MADRIDInventors: Jose Luis Fernandez Garcia, Jaime Gosalvez Berenguer, German Bou Arevalo, Maria Tamayo Novas, Rebeca Santiso Brandariz
-
Publication number: 20160235834Abstract: The present invention refers to a method for the production of live attenuated bacterial strains, suitable as vaccine candidates, comprising the steps of: A. providing a bacterial strain capable of expressing glutamate racemase and possibly D-amino acid transaminase and comprising a peptidoglycan cell wail, and B. inactivating the gene or genes encoding for the glutamate racemase enzyme and, if needed, the gene or genes encoding for the enzyme D-amino acid transaminase in such way that the bacterial strain is no longer capable of expressing a functional glutamate racemase and/or a functional D-amino acid transaminase; wherein the inactivation of said genes causes said bacterial strain to be auxotrophic for D-glutamate.Type: ApplicationFiled: October 13, 2014Publication date: August 18, 2016Inventors: Germán Bou Arévalo, María Clara Póvoa Cabral, Astrid Pèrez Gómez, María Merino Carballeira, Alejandro Beceiro Casas, Patricia García Fernández
-
Publication number: 20160208307Abstract: The present invention relates to am method for the rapid evaluation of bacterial susceptibility or non-susceptibility of bacteria to antibiotics that inhibit protein synthesis. The rationale is to identify bacterial responses that depend or are influenced by protein synthesis. If this response is prevented or reduced by the antibiotic that inhibits the protein synthesis, the bacteria are susceptible to this antibiotic. Otherwise, if the response keeps similar despite the incubation with the antibiotic, the bacteria are no susceptible or resistant to this antibiotic.Type: ApplicationFiled: January 19, 2016Publication date: July 21, 2016Applicant: ABM TECHNOLOGIES, LLCInventors: José Luis FERNÁNDEZ GARCÍA, Jaime GOSÁLVEZ BERENGUER, Germán BOU ARÉVALO, Maria TAMAYO NOVAS, Rebeca SANTISO BRANDARIZ, Fátima María OTERO FARIÑA
-
Publication number: 20150010940Abstract: A method of rapidly evaluating the susceptibility of a strain of bacteria to a cell wall synthesis inhibiting antibiotic based on an assessment of cell enlargement in response to doses of the cell wall synthesis inhibiting antibiotic which are correlated to breakpoints of bacterial susceptibility.Type: ApplicationFiled: July 2, 2014Publication date: January 8, 2015Applicant: ABM TECHNOLOGIES, LLCInventors: Jose Luis Fernandez Garcia, Jaime Gosalvez Berenguer, Rebeca Santiso Brandariz, Maria Tamayo Novas, German Bou Arevalo
-
Publication number: 20140206573Abstract: The present invention relates to a method for evaluating the integrity of the cell wall of the bacteria present in a culture in the presence of an antibiotic acting on the bacterial cell wall which, from a practical point of view, allows quickly determining if a bacterium is sensitive or resistant to an antibiotic acting on the bacterial cell wall. Likewise, the present invention also relates to a lysis solution applicable in the preceding method, specifically affecting bacteria having the cell wall damaged by the action of an antibiotic acting on the bacterial cell wall, which allows distinguishing bacteria sensitive to said antibiotic from those resistant to said antibiotic.Type: ApplicationFiled: July 26, 2012Publication date: July 24, 2014Applicant: UNIVERSIDAD AUTONOMA DE MADRIDInventors: José Luis Fernandesz Garcia, Jaime Gosalvez Berenguer, German Bou Arevalo, María Tamaoyo Novas, Rebeca Santisto Brandariz